6.085USD-4.17%Mkt Cap: 251.90M USDP/E: —Last update: 2026-05-22
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It …
Industry Peers
Medical Devices152.25BUSDP/E 24.5
85.88BUSDP/E 24.2
53.45BSEKP/E 22.7
53.33BSEKP/E 98.9
52.13BDKKP/E 22.1
38.61BEURP/E 18.3
23.15BSEK—
22.25BEURP/E 23.4
loading…
Indicators:|
Key Statistics
Company
Market Cap251.90M USD
Enterprise Value55.81M USD
Revenue (TTM)127.48M USD
Gross Profit103.01M USD
Net Income (TTM)-38.94M USD
Revenue/Share3.105 USD
Last Price6.085 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees461
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.34
PEG—
EV/EBITDA-1.07
EV/Revenue0.44
P/S2.06
P/B0.95
EPS (TTM)-1.13
EPS (Forward)-0.56
52W Range
5.3007% of range16.48
52W High16.48 USD
52W Low5.300 USD
Profitability
Gross Margin76.60%
Oper. Margin-57.71%
EBITDA Margin-40.81%
Profit Margin-28.96%
ROE-14.13%
ROA-12.49%
Growth
Revenue Growth-18.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.51M USD
CapEx (TTM)3.83M USD
FCF Margin-0.76%
FCF Yield-0.38%
Net Debt-207.05M USD
Net Debt/EBITDA3.98
Balance Sheet
Debt/Equity0.04
Current Ratio10.20
Quick Ratio8.78
Book Value/Sh6.685 USD
Cash/Share5.263 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.1 (Hold)
Target (Mean)8.786 USD
Target Range7.500 USD – 11.00 USD
# Analysts7
Ownership
Shares Out.41.40M
Float39.18M
Insiders5.66%
Institutions93.31%
Short Interest
Short Ratio7.6d
Short % Float14.21%
Short % Out.13.46%
Shares Short5.57M
Short (prev mo.)5.06M
Technical
SMA 506.734 (-9.6%)
SMA 2008.665 (-29.8%)
Beta1.24
S&P 52W Chg28.31%
Avg Vol (30d)688.00K
Avg Vol (10d)631.14K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—